Unethical informed consent caused by overlooking poorly measured nocebo effects

Area of Science:

• Medical Ethics
• Psychosomatic Medicine
• Clinical Trial Design

Background:

• The nocebo effect, where negative expectations lead to adverse outcomes, is under-researched compared to the placebo effect.
• Existing research often fails to distinguish nocebo effects from natural disease progression.
• Ethical informed consent primarily focuses on patient autonomy and intervention risks, neglecting the communication of risk information.

Purpose of the Study:

• To highlight the epistemic and ethical neglect of the nocebo effect.
• To propose a methodology for accurately measuring the nocebo effect.
• To advocate for the integration of the nocebo effect into ethical informed consent procedures.

Main Methods:

• Critically analyze the distinction between nocebo effects and adverse events from natural history.
• Argue for the use of untreated control groups to isolate and quantify nocebo effects.
• Examine the ethical implications of risk communication in clinical settings.

Main Results:

• Adverse events in placebo groups are not always attributable to the nocebo effect.
• The magnitude of nocebo effects can be accurately measured using appropriate control groups.
• The nocebo effect poses a tangible risk of harm to patients.

Conclusions:

• The nocebo effect requires dedicated measurement and consideration in research and clinical practice.
• Ethical informed consent must incorporate the principle of non-maleficence, addressing potential harm from nocebo effects.
• Risk communication strategies need to be carefully designed to mitigate the nocebo effect and uphold patient well-being.